|
|
|
|
|
|
Sponsored by: |
L.A.L Clinica Pesquisa e Desenvolvimento Ltda. |
Information provided by: | L.A.L Clinica Pesquisa e Desenvolvimento Ltda. |
ClinicalTrials.gov Identifier: | NCT00701623 |
Burns are injuries caused by agents thermal, chemical, electrical or radioactive who act in the tissue lining of the human body and may partially or totally destroy the skin and its annexes, to the deeper layers, as subcutaneous tissue, muscles, tendons and bones .
Studies show that topical heparin has, in addition to the already known anticoagulant activity, anti-inflammatory properties, analgesic, and neoangiogenic, stimulating blood flow and increasing the repair of the fabric as well as the restoration of collagen and reepiteliztion. Moreover, the use of heparin reduces the need for painful medical procedures, as debridations, surgeries and transplants The intention of this work is to verify the effectiveness and safety of sodium heparin in the treatment of burns of the skin.
Condition | Intervention | Phase |
Burns |
Drug: heparin Drug: folder water |
Phase II Phase III |
MedlinePlus related topics: | Blood Thinners Burns Drinking Water |
Drug Information available for: | Heparin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Clinical Efficacy of Product Alimax ® (Sodic Heparin) in Treatment of Burns: Comparative Study of Raw Materials Between Two Suppliers |
Estimated Enrollment: | 84 |
Study Start Date: | June 2008 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
patients treated with heparin
|
Drug: heparin
patients will receive the application of one of two types of heparin directly on the injured area
|
2: Experimental
Patients treated with heparin
|
Drug: heparin
patients will receive the application of one of two types of heparin directly on the injured area
|
3: Active Comparator
patients treated with folder water directly on the injured area
|
Drug: folder water
patients will receive the application of folder water directly on the injured area
|
Patients with burns that come to the emergency room will be informed about the
Inclusion Criteria
Exclusion Criteria
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Alexandre Frederico, Investigator | 55-19-3829-3822 | dr.alexandre.@lalclinica.com.br |
Brazil, Sao Paulo | |||||
LAL Clinica PPesquisa e Desenvolvimento | |||||
Valinhos, Sao Paulo, Brazil |
L.A.L Clinica Pesquisa e Desenvolvimento Ltda. |
Responsible Party: | LAL Clinica ( Alexandre Frederico ) |
Study ID Numbers: | HEPCRI0208 |
First Received: | June 17, 2008 |
Last Updated: | June 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00701623 |
Health Authority: | Brazil: National Health Surveillance Agency |
|
|
|
|